Early Access — free while we kick the tires
EdgarHawk

POON CHRISTINE A

Director

Director
2 filings analyzed · 1 company · Latest 2025-10-31

Companies

Company Buys Sells Direction
REGENERON PHARMACEUTICALS, INC. REGN 0 16 Net selling

Activity

October 2025
Sell
6,500 shares
$4,252,745
Significance 7/10

Director Christine A. Poon sells 6,500 shares ($4.3M) at $654.27 avg; holds 5,064 shares post-transaction.

Director Christine A. Poon executed 6 separate sales totaling 6,500 shares for $4,252,745.32 on 2025-10-29, reducing her holding by 56.2% from 11,564 shares to 5,064 shares. The blended average sale price of $654.27 is modestly above the current price of $651.80, though notably below the 52-week high of $928.61. Her prior 5 sales at REGN (all on 2024-08-15) showed strong timing discipline at the 90-day horizon, with all 5 trades posting negative 90-day returns—a 100.00% well-timed rate. Her cross-ticker track record similarly reflects a 100.00% 90d well-timed rate across 12 prior sells. The material reduction in her position, combined with a track record of disciplined prior exits at this ticker, suggests deliberate portfolio reduction rather than routine liquidation.

August 2024
Sell
10,838 shares
$12,552,284
Significance 7/10

Director Christine A Poon sold 10,838 shares of REGN for $12.6M across 7 transactions on 2024-08-15, reducing holdings by 83.3%.

Christine A Poon (Director) executed 7 separate sales totaling 10,838 shares for $12,552,284.50 at prices ranging from $1,155.72 to $1,161.32 on 2024-08-15, leaving 2,172 shares post-transaction. This represents a -83.3% reduction of her pre-transaction holdings of 13,010 shares. The scale of the reduction—nearly a complete exit from her publicly-disclosed position—exceeds routine portfolio activity. Notably, her prior 5 sales at REGN were uniformly well-timed at the 90-day mark, with all prior REGN trades showing negative 90-day returns (-1.6% to -5.0%), indicating a historical pattern of selling before price declines. The current stock price of $1196.88 stands 0.0% from the 52-week high and has appreciated +12.5% over 30 days and +20.4% over 90 days since the August 15 sale, showing post-sale upward momentum. This transaction warrants close observation to determine whether the sustained recent price strength represents a departure from her prior pattern of well-timed exits.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access